178 related articles for article (PubMed ID: 26721284)
1. Companies to pay $39.5m in OxyContin and Risperdal cases.
McCarthy M
BMJ; 2015 Dec; 351():h7018. PubMed ID: 26721284
[No Abstract] [Full Text] [Related]
2. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
Cicero TJ; Inciardi JA; Muñoz A
J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
[TBL] [Abstract][Full Text] [Related]
3. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
4. Renovations Needed: the FDA's Floor/Ceiling Framework, Preemption, and the Opioid Epidemic.
Abrams MR
Mich Law Rev; 2018 Oct; 117(1):143-71. PubMed ID: 30300989
[TBL] [Abstract][Full Text] [Related]
5. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
6. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
7. A profile of OxyContin addiction.
Hays LR
J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
[TBL] [Abstract][Full Text] [Related]
8. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report.
Government Accounting Office
J Pain Palliat Care Pharmacother; 2004; 18(3):109-13. PubMed ID: 15364638
[TBL] [Abstract][Full Text] [Related]
9. Drug Companies' Liability for the Opioid Epidemic.
Haffajee RL; Mello MM
N Engl J Med; 2017 Dec; 377(24):2301-2305. PubMed ID: 29236640
[No Abstract] [Full Text] [Related]
10. Distribution of Abatement Funds Arising From US Opioid Litigation.
Alexander GC; Mansour O
JAMA; 2022 Nov; 328(19):1901-1902. PubMed ID: 36306147
[TBL] [Abstract][Full Text] [Related]
11. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
[No Abstract] [Full Text] [Related]
12. Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe cancer pain.
Yu SY;
Oncology; 2008; 74 Suppl 1():46-51. PubMed ID: 18758197
[TBL] [Abstract][Full Text] [Related]
13. Industry influence and Health Canada's responsibility: lessons from the opioid epidemic in Canada.
Bavli I
Addiction; 2020 Sep; 115(9):1605-1606. PubMed ID: 31845436
[No Abstract] [Full Text] [Related]
14. The 'poor man's heroin'. An Ohio surgeon helps feed a growing addiction to OxyContin.
Cohen G
US News World Rep; 2001 Feb; 130(6):27. PubMed ID: 11216230
[No Abstract] [Full Text] [Related]
15. US drug maker resisted changes to its opioid dosing recommendations to protect revenue, newspaper alleges.
McCarthy M
BMJ; 2016 May; 353():i2683. PubMed ID: 27169875
[No Abstract] [Full Text] [Related]
16. Revisiting Factor VIII cases: is it time for an agency adjudication system?
Su YC
Food Drug Law J; 2008; 63(4):943-61. PubMed ID: 19601390
[No Abstract] [Full Text] [Related]
17. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
Struve CT
Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
[No Abstract] [Full Text] [Related]
18. OxyContin in Ontario: the multiple materialities of prescription painkillers.
King S
Int J Drug Policy; 2014 May; 25(3):486-93. PubMed ID: 24612641
[TBL] [Abstract][Full Text] [Related]
19. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
Chodock R; Yolkut D; Connolly DR
Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
[TBL] [Abstract][Full Text] [Related]
20. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
Levy E
Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
